Assess whether the 505(b)(2) bridge is legally and scientifically enough

SITUATION RWE protocol that may not meet regulator expectations arrived with a CRL citing manufacturing, not efficacy for labeling negotiator. That is a Pharma & Life Sciences CMC and Development Pathways decision on the 505(b)(2) bridge is in a 505(b)(2) program relying on literature plus a bridging study.

DECISION Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after a CRL citing manufacturing, not efficacy.

HYPOTHESES TO TEST 1. The population in RWE protocol that may not meet regulator expectations is the one a CRL citing manufacturing, not efficacy named, so Proceed under protocol follows for this CMC and Development Pathways file. 2. The population in RWE protocol that may not meet regulator expectations is adjacent only to a CRL citing manufacturing, not efficacy; Pause the pathway is the honest Pharma & Life Sciences call. 3. A 505(b)(2) program relying on literature plus a bridging study already contained a CRL citing manufacturing, not efficacy before RWE protocol that may not meet regulator expectations arrived; no new CMC and Development Pathways path. 4. Provenance on RWE protocol that may not meet regulator expectations after a CRL citing manufacturing, not efficacy is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Check whether RWE protocol that may not meet regulator expectations supports the labeled claim labeling negotiator would keep. 2. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 3. Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after a CRL citing manufacturing, not efficacy. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read RWE protocol that may not meet regulator expectations against a CRL citing manufacturing, not efficacy and write the one fact that would move the 505(b)(2) bridge is for labeling negotiator.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (RWE protocol that may not meet regulator expectations after a CRL citing manufacturing, not efficacy). Lead with the Pharma & Life Sciences option RWE protocol that may not meet regulator expectations can support after a CRL citing manufacturing, not efficacy, then the two facts that force it, then the Monday action for labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study.